Lonza Group Stock Trades Steady Amid Recent Earnings and Growth Investments

Lonza Group stock traded steadily as investors weighed in on its recent earnings and growth investments. The Swiss life-sciences company, listed on SIX Swiss Exchange, reported multi-billion Swiss franc revenue in its latest annual results, with total revenue ranging from CHF 6 billion to CHF 7 billion.

This growth was largely driven by biologics manufacturing contracts and demand for advanced therapies, even as legacy small-molecule activities and specialty ingredients segments saw more moderate dynamics. The company's adjusted EBITDA margin appears in the mid-twenties percent range, roughly a few percentage points below its prior-year peak.

Lonza has targeted mid-single-digit to low-double-digit percentage revenue growth over the medium term, supported by its biologics and small molecules pipelines. The company's investment plan in biologics and other high-complexity manufacturing has consumed substantial capital, sometimes amounting to several hundred million Swiss francs per year or more.